+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Drugs In Development, 2021

  • ID: 5359568
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 47 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Curacle Co Ltd
  • PHusis Therapeutics Inc
  • Viracta Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

According to the recently published report '3 Phosphoinositide Dependent Protein Kinase 1 - Drugs In Development, 2021'; 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - 3 Phosphoinositide Dependent Protein Kinase 1 is an enzyme encoded by the PDPK1 gene Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It negatively regulates the TGF-beta-induced signaling by modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta.

The report '3 Phosphoinositide Dependent Protein Kinase 1 - Drugs In Development, 2021' outlays comprehensive information on the 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Coronavirus Disease 2019 (COVID-19), Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Skin Cancer and Solid Tumor.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)
  • The report reviews 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Curacle Co Ltd
  • PHusis Therapeutics Inc
  • Viracta Therapeutics Inc
Introduction
  • Report Coverage
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Overview

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • Curacle Co Ltd
  • PHusis Therapeutics Inc
  • Viracta Therapeutics Inc
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Drug Profiles

AR-12 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CU-05 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PHT-427 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit PDK1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SNS-510 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Dormant Products

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases
  • Oct 12, 2020: Sunesis Pharmaceuticals announces presentation of SNS-510 preclinicaldData at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • Sep 21, 2020: Study shows the experimental drug AR-12 could be a promising COVID-19 treatment
  • Jul 07, 2020: Sunesis Pharmaceuticals provides corporate update
  • Oct 16, 2019: Sunesis Pharmaceuticals announces presentation of SNS-510 preclinical data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • Nov 09, 2015: Sunesis Pharmaceuticals Presents Preclinical Data From PDK1 Inhibitor SNS-510 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis
  • Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
  • Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
  • Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
  • Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition
  • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
  • May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
  • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
  • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
  • Aug 27, 2009: Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Curacle Co Ltd, 2021
  • Pipeline by PHusis Therapeutics Inc, 2021
  • Pipeline by Viracta Therapeutics Inc, 2021
  • Dormant Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Curacle Co Ltd
  • PHusis Therapeutics Inc
  • Viracta Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll